US$ 28.60
glp-1 video Video: Non-insulin injectable antidiabetic drugs - agonists and amylinomimetics: Nursing pharmacology VIDEO] GLP-1 Manufacturing's New Bottlenecks
Description
De Paoli, Monica, et al
![glp-1 video Video: Non-insulin injectable antidiabetic drugs - agonists and amylinomimetics: Nursing pharmacology VIDEO] GLP-1 Manufacturing's New Bottlenecks](https://vertassets.blob.core.windows.net/image/a3beeff3/a3beeff3-4fde-4c50-963d-27548947aa8c/375_250-process_control_for_monoclonal_antibodies__recombinant_proteins__probiotics__glp_1_production_gettyimages_2281853896.jpg)
Understanding these mechanisms is essential when considering long-term treatment outcomes, as the body's response to these medications can evolve over time through various physiological adaptations
![glp-1 video Video: Non-insulin injectable antidiabetic drugs - agonists and amylinomimetics: Nursing pharmacology VIDEO] GLP-1 Manufacturing's New Bottlenecks](https://i.ytimg.com/vi/1qw59S7BP44/maxresdefault.jpg)
A crucial knowledge gap is the lack of head-to-head comparative studies evaluating their ocular effects
No significant differences were demonstrated for GLP-1, GIP or glucagon z-scores in the group with metabolic syndrome compared to without metabolic syndrome